View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

US clinical trial sites are most affected due to the Covid-19 pandemic

By Victoria Smith

With the recent development of the ongoing Covid-19 pandemic, there has been increased urgency for industry and non-industry sponsors to concentrate on discovering a suitable therapeutic or vaccine for this highly contagious viral disease. Therefore, more Covid-19 clinical trials are being prepared and launched, while a vast number of clinical trials for non-Covid-19 indications are experiencing setbacks.

High profile pharmaceutical companies have declared interruptions to intended and continuing trials, delaying trial start dates and pausing subject enrolment. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena